Intensity modulated proton therapy for early-stage glottic cancer: high-precision approach to laryngeal function preservation with exceptional treatment tolerability

Radiation Oncology

Research

Karim Plath¹  Peter K. Plinkert¹  Gerhard Dyckhoff¹  Henrik Franke²  Thomas Held³  Kristin Lang³  Lukas Bauer³  Katharina Weusthof³  Tanja Eichkorn³  Sebastian Regnery³  Sebastian Adeberg⁴  Semi B. Harrabi⁴  Jürgen Debus⁴  Klaus Herfarth⁴ 

[1] Department of Otorhinolaryngology, Head and Neck Surgery, University of Heidelberg, Heidelberg, Germany;Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany;Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany;Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany;Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany;National Center for Tumor diseases (NCT), Heidelberg, Germany;Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany;Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany;National Center for Tumor diseases (NCT), Heidelberg, Germany;Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany;Heidelberg Ion Beam Therapy Center (HIT), Heidelberg, Germany;German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany;

关键词: Head and neck cancer;    Laryngeal cancer;    Squamous cell carcinoma;    Proton therapy;    Glottic cancer;    Radiotherapy;    Treatment toxicity;    Laryngeal preservation;   

DOI  :  10.1186/s13014-022-02144-w

 received in 2022-01-28, accepted in 2022-10-12,  发布年份 2022

来源: Springer

【 摘 要 】

BackgroundDue to the increasing expertise in transoral laser surgery and image-guided radiation therapy, treatment outcomes have recently improved in patients with early-stage glottic cancer. The objective of the current study was to evaluate intensity-modulated proton therapy (IMPT) as novel treatment option.MethodsA total of 15 patients with T1-2N0 glottic squamous cell carcinoma, treated between 2017 and 2020, were evaluated. Toxicity was recorded according to the Common Terminology Criteria for Adverse Events (CTCAE) v4.03.ResultsThe majority were T1a/b tumors (66.7%) and no patient had lymph node or distant metastases. The median total dose was 70 Gy relative biological effectiveness (RBE) (range 66–70 Gy RBE). The one- and two-year OS and metastases-free survival were 100%. One patient developed local failure and received salvage laryngectomy. No higher-grade acute or late toxicity was reported. The mean number of CTCAE grade I and II overall toxicity events per patient was 4.1 (95%-[confidence interval] CI 3.1–5.3) and 1.0 (95%-CI 0.5–1.5).ConclusionHigh-precision proton therapy of T1-2N0 glottic cancer resulted in exceptional treatment tolerability with high rates of laryngeal function preservation and promising oncological outcome. IMPT has the potential to become a standard treatment option for patients with early-stage laryngeal cancer.

【 授权许可】

CC BY   
© The Author(s) 2022

【 图 表 】

41408_2022_764_Article_IEq1.gif